Cerebrospinal fluid cytokine dynamics differ between alzheimer disease patients and elderly controls

Alzheimer Disease and Associated Disorders

Volumn 26, Issue 4, 2012, Pages 322-328

  Llano, Daniel A ^a,b   Li, Jinhe ^a   Waring, Jeffrey F ^a   Ellis, Teresa ^a   Devanarayan, Viswanath ^a   Witte, David G ^a   Lenz, Robert A ^a  

^a ABBOTT LABORATORIES   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Alzheimer; cerebrospinal fluid; cytokine; dementia; diurnal

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN TISSUE; LIMIT OF DETECTION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84865487498     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e31823b2728     Document Type: Article

References (33)

1. Reale M, Greig N, Kamal M. Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseases. Mini Rev Med Chem. 2009;9:1229-1241.
2. McGeer EG, McGeer PL. Neuroinflammation in Alzheimer's Disease and mild cognitive impairment: a field in its infancy. J Alzheimer Dis. 2010;19:355-361.
3. Sheng J, Mrak R, Griffin W. Neuritic plaque evolution in Alzheimer's disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms. Acta Neuropathol. 1997;94:1-5.
4. Lue LF, Brachova L, Civin WH, et al. Inflammation, a beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J Neuropathol Exp Neurol. 1996;55:1083-1088.
5. Griffin W, Stanley LC, Ling C, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci. 1989;86: 7611-7615.
6. Du Y, Dodel RC, Eastwood BJ, et al. Association of an interleukin 1(alpha) polymorphism with Alzheimer's disease. Neurology. 2000;55:480-484.
7. Bona DD, Candore G, Franceschi C, et al. Systematic review by meta-analyses on the possible role of TNF-(alpha) polymorphisms in association with Alzheimer's disease. Brain Res Rev. 2009;61:60-68.
8. Ferná ndez JA, Rojo L, Kuljis RO, et al. The damage signals hypothesis of Alzheimer's disease pathogenesis. J Alzheimer Dis. 2008;14:329-333.
9. Swardfager W, Lanctô t K, Rothenburg L, et al. A meta-analysis of cytokines in Alzheimer's Disease. Biol Psychiatry. 2010;68: 930-941.
10. Sunderland T, Linker G, Mirza N, et al. Decreased (beta)-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer Disease. JAMA. 2003;289:2094-2103.
11. Bateman RJ, Wen G, Morris JC, et al. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology. 2007;68:666-669.
12. Li J, Llano DA, Ellis T, et al. Effect of human cerebrospinal fluid sampling frequency on Ab levels. Alzheimer Dement. 2011. (Accepted).
13. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
14. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364.
15. Rota E, Bellone G, Rocca P, et al. Increased intrathecal TGFb1, but not IL-12, IFN-g and IL-10 levels in Alzheimer's disease patients. Neurol Sci. 2006;27:33-39.
16. Galimberti D, Venturelli E, Fenoglio C, et al. Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration. J Neurol. 2008;255:539-544.
17. Tarkowski E, Wallin A, Regland B, et al. Local and systemic GM-CSF increase in Alzheimer's disease and vascular dementia. Acta Neurol Scand. 2001;103:166-174.
18. Mart?́nez M, Ferná ndez-Vivancos E, Frank A, et al. Increased cerebrospinal fluid Fas (Apo-1) levels in Alzheimer's disease: relationship with IL-6 concentrations. Brain Res. 2000;869: 216-219.
19. Tarkowski E, Andreasen N, Tarkowski A, et al. Intrathecal inflammation precedes development of Alzheimers disease. J Neurol Neurosurg Psychiatry. 2003;74:1200-1205.
20. Jia JP, Meng R, Sun YX, et al. Cerebrospinal fluid tau, A(beta)1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. Neurosci Lett. 2005;383:12-16.
21. Galimberti D, Schoonenboom N, Scheltens P, et al. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer Disease. Arch Neurol. 2006;63:538-543.
22. Zhang J, Sokal I, Peskind ER, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008;129:526-529.
23. De Luigi A, Pizzimenti S, Quadri P, et al. Peripheral Inflammatory response in Alzheimer's disease and multiinfarct dementia. Neurobiol Dis. 2002;11:308-314.
24. Licastro F, Pedrini S, Caputo L, et al. Increased plasma levels of interleukin-1, interleukin-6 and (alpha)-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J Neuroimmunol. 2000;103:97-102.
25. Ö ztü rk C, Ö zge A, Yalin OÖ, et al. The diagnostic role of serum inflammatory and soluble proteins on dementia subtypes: correlation with cognitive and functional decline. Behavl Neurol. 2007;18:207-215.
26. Boon JM, Abrahams PH, Meiring JH, et al. Lumbar puncture: anatomical review of a clinical skill. Clinl Anat. 2004;17: 544-553.
27. Tan ZS, Beiser AS, Vasan RS, et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham study. Neurology. 2007;68:1902-1908.
28. Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective (beta)-amyloid clearance pathways in aging Alzheimer's Disease mice. J Neurosci. 2008;28:8354-8360.
29. Coogan AN, Wyse CA. Neuroimmunology of the circadian clock. Brain Res. 2008;1232:104-112.
30. Volicer L, Harper DG, Manning BC, et al. Sundowning and circadian rhythms in Alzheimer's Disease. Am J Psychiatry. 2001;158:704-711.
31. Wu Y-H, Swaab DF. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. Sleep Med. 2007;8:623-636.
32. Sullivan EV, Shear PK, Mathalon DH, et al. Greater abnormalities of brain cerebrospinal fluid volumes in younger than in older patients with Alzheimer's disease. Arch Neurol. 1993;50:359-373.
33. Popescu BO, Toescu EC, Popescu LM, et al. Blood-brain barrier alterations in ageing and dementia. J Neurolo Sci. 2009;283:99-106.